Jason Luke, MD: The Role of LDH, Age, and Sites of Disease in Durability of Response
What role might Sarah's LDH, age, and sites of disease play in the durable response that she experienced?
CASE: Metastatic Melanoma
Sarah is a 50-year-old Caucasian postal worker who presented to her primary care physician with multiple, skin-colored nodules and palpable lymph nodes. .
- A workup, biopsy, and mutation test was conducted, which revealed BRAF V600E mutation-positive melanoma that had metastasized to the lymph nodes, subcutaneous tissue, and right adrenal gland.
- ECOG performance status is 0 and her LDH levels are normal.
The patient was started on the combination of dabrafenib and trametinib. She experienced a durable complete response and has remained on therapy for 36 months.
Recent Videos
Related Content
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
